Bruker (BRKR) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic focus and financial outlook

• Emphasis on profitability, margin expansion, and double-digit EPS growth through 2030, following a 70% revenue increase from 2020 to 2024 and a challenging 2025.

• Targeting margin improvement from mid-teens to low/mid-20s, 250–300 basis points organic margin expansion in FY26, and $120 million in cost savings by 2026.

• Project Accelerate 3.0 expands into aftermarket, sticky revenues, and new growth areas such as clinical microbiology, molecular diagnostics, and automated AI lab tools.

• FY25 revenue guidance at ~$3.43 billion, up 2%, with flat to low single-digit organic growth expected in FY26.

• Double-digit non-GAAP EPS CAGR targeted for FY27–30, with 200–300 bps above-market revenue CAGR.

Market and product developments

• Significant investments and acquisitions in proteomics, metabolomics, spatial biology, and scientific software have transformed the portfolio for the post-genomic era.

• New product launches in spatial biology (CosMx Whole Transcriptome Panel, CosMx 2.0, CellScape) and mass spectrometry (TIMS Omni, TIMS Metabo, timsOmni) are gaining traction, with strong consumables growth and early orders.

• Automated, digitized, AI-ready lab tools now represent a $100 million business with high growth potential, targeting a $9–12 billion market with 15–25% CAGR.

• Defense detection and semiconductor metrology businesses are growing, with defense tech expected to reach $100 million and YoY growth over 30%, and expanded tools for advanced packaging and AI chip production.

• Large multi-year orders in superconductors and magnetic resonance support multi-year growth and remove previous headwinds.

Clinical microbiology and molecular diagnostics expansion

• MALDI Biotyper platform has nearly 8,000 systems installed; expansion into rapid AST and syndromic panels for infectious disease diagnostics.

• ELITechGroup acquisition boosts molecular diagnostics, now a $500 million business with high aftermarket revenue and margins; over 65% of microbiology and MDx revenue is recurring.

• Plans to launch affordable syndromic panels and enter the U.S. market, with S2A MDx systems (InGenius, BeGenius) and clinical trials starting in 2026.

• Addition of Wave Rapid AST platform, targeting FDA clearance and U.S. launch in 2026, expected to address a $400 million market for sepsis and antimicrobial resistance and further differentiate the clinical microbiology business.

• Integration of rapid AST with ID solutions aims to revolutionize clinical microbiology workflows.